AIMS To correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel. Data from recent trials and registries suggest a link between increased risk of bleeding and cardiovascular mortality. Howe...

OBJECTIVE Prehospital use of antiplatelet agents has been associated with an increased risk for intracranial hemorrhage (ICH) as well as a secondary increase in ICH volume after the initial hemorrhage. Strategies to reestablish platelet aggregation are used in clinical practice, but without any established guidelines or recommendations. This article serves to evaluate the literature regarding "...

We tested the antiplatelet effects of low-dose aspirin in patients with occlusive cerebrovascular disease, because conventional dosage aspirin inhibits vascular synthesis of prostacyclin at the same time that it inhibits platelets. The effects on platelet function and thromboxane A2 synthesis of 40 mg of aspirin daily or 40 mg aspirin plus dipyridamole were measured in 23 patients starting with...

Inhibit Platelet Aggregation To the Editor: Lau et al1 recently reported that coadministration of CYP3A4metabolized statins (atorvastatin, simvastatin, and lovastatin) but not pravastatin (fluvastatin and rosuvastatin) inhibited the “antiplatelet activity of clopidogrel in a dose-dependent manner,” using an in vitro point-of-care MICROS cell counter (ABX Diagnostics) and the Plateletworks test ...

Cardiovascular diseases are the leading cause of morbidity in many countries worldwide. Antiplatelet therapy has been successful in reducing mortality and morbidity in cardiovascular diseases. Because inflammation is central to atherothrombosis, agents with both antiinflammatory and antithrombotic properties may be critical to preventing the considerable morbidity and mortality associated with ...

-Aminocaproic acid (EACA) is a synthetic low molecular drug with antifibrinolytic activity. However, treatment with this drug can be incidentally associated with an increased thrombotic tendency. The aim of the present work was to test synthetic EACA derivatives for their antiplatelet activities. We investigated the effect of three EACA derivatives with antifibrinolytic activity: I. -aminocapro...

Ferulic acid (FA) is widely considered as a biologically active component in Angelica sinensis, and used as one of the marker compounds for the quality control of Angelica sinensis. However, in A. sinensis, FA mainly exists as its ester, coniferyl ferulate (CF). CF is unstable and readily hydrolyzed into FA during conventional extraction. Herein, their antiplatelet aggregation activities and re...

Platelet activation and aggregation have been shown to play a central role in thromboembolic disorders (20,35,37). Platelets are activated by a variety of agonists. They adhere to the injured blood vessel walls and, subsequently, aggregate. These processes lead to the formation of occlusive thrombi in the lumen of the injured vessel (16,23,53). The efficacy of such common antiplatelet agents as...

We tested the antiplatelet effects of low-dose aspirin in patients with occlusive cerebrovascular disease, because conventional dosage aspirin inhibits vascular synthesis of prostacyclin at the same time that it inhibits platelets. The effects on platelet function and thromboxane A2 synthesis of 40 mg of aspirin daily or 40 mg aspirin plus dipyridamole were measured in 23 patients starting with...